Clinical Trials Logo

FSGS clinical trials

View clinical trials related to FSGS.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04009668 Completed - Clinical trials for Focal Segmental Glomerulosclerosis

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Start date: October 2, 2019
Phase: Phase 2
Study type: Interventional

The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

NCT ID: NCT03536754 Completed - Clinical trials for Focal Segmental Glomerulosclerosis

A Study of CCX140-B in Subjects With FSGS

Start date: May 17, 2018
Phase: Phase 2
Study type: Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia